Wave Life Sciences Ltd., a clinical-stage biotechnology company focused on RNA medicines, has released its financial results for the second quarter ended June 30, 2025. The company also provided a comprehensive business update, highlighting significant advancements in its clinical programs and strategic initiatives. Financial Highlights For the second quarter of 2025, Wave Life Sciences reported a net loss of $50.5 million, compared to a net loss of $32.9 million in the same period last year. Revenue for the quarter was $8.7 million, down from $19.7 million in the prior year quarter. Research and development expenses increased to $43.5 million from $40.4 million, while general and administrative expenses rose to $18.0 million from $14.3 million. The company ended the quarter with $208.5 million in cash and cash equivalents, down from $302.1 million as of December 31, 2024. Business and Operational Highlights Wave Life Sciences has made significant progress in its clinical programs.